Lanreotide autogel in acromegaly - a decade on.

about

A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry.

P2860

Q38373377-89CDA49D-B41B-4040-9918-B00BC4670F0D

P2860

Lanreotide autogel in acromegaly - a decade on.

Item

http://www.wikidata.org/entity/Q38259409

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Lanreotide autogel in acromegaly - a decade on.

@en

type

Item

label

Lanreotide autogel in acromegaly - a decade on.

@en

prefLabel

Lanreotide autogel in acromegaly - a decade on.

@en

P1476

Lanreotide autogel in acromegaly - a decade on

@en

P2093

Julie Lynch

http://www.w3.org/2001/XMLSchema#string

Robert D Murray

http://www.w3.org/2001/XMLSchema#string

Steve M Orme

http://www.w3.org/2001/XMLSchema#string

Vincent Chau

http://www.w3.org/2001/XMLSchema#string

P2860

Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry.

Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone.

Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.

Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.

Biomimetic organization: Octapeptide self-assembly into nanotubes of viral capsid-like dimension.

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly.

Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis.

Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly

P304

2681-2692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2014.970173

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nikolaos Kyriakakis

P577

2014-10-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266746033

http://www.w3.org/2001/XMLSchema#string

P698

25307803

http://www.w3.org/2001/XMLSchema#string

Lanreotide autogel in acromegaly - a decade on.

about

P2860

P2860

Lanreotide autogel in acromegaly - a decade on.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698